Biomanufacturing in space represents a frontier in biotechnology, offering unique advantages for pharmaceutical production, regenerative medicine, and synthetic biology. Unlike terrestrial manufacturing, space-based bioprocessing leverages microgravity to influence biological and chemical interactions in ways that cannot be replicated on Earth. Microgravity conditions can enhance cell growth, improve protein crystallization, and enable three-dimensional tissue culture without the structural limitations imposed by gravity. These advantages open new possibilities for developing advanced therapeutics, bioengineered tissues, and novel biomaterials that could accelerate drug discovery and revolutionize personalized medicine.1,2
Introduction
The significance of space-based biomanufacturing extends beyond scientific curiosity; it holds profound implications for healthcare, industry, and space exploration. The ability to produce biopharmaceuticals in microgravity could lead to more stable and effective drugs, particularly for complex protein structures. Additionally, the field intersects with regenerative medicine through the use of stem cells and biofabrication technologies to develop tissues and organoids with improved structural and functional properties. In synthetic biology, space-based biomanufacturing offers new opportunities to engineer microbial systems that can produce essential biomolecules, biopolymers, and even food, supporting long-term human spaceflight and planetary colonization efforts.3,4
The History of Biological Research in Space
The origins of biomanufacturing in space trace back to early spaceflight experiments focused on the effects of microgravity on living organisms. During the 1970s and 1980s, space agencies such as the National Aeronautics and Space Administration (NASA) and the European Space Agency (ESA) conducted studies aboard Skylab and Spacelab, examining how spaceflight altered microbial growth, cellular processes, and protein formation. These foundational studies revealed that microgravity could enhance certain biological processes, such as protein crystallization, leading to improvements in drug development and structural biology research.1,5
The International Space Station (ISS) has played a crucial role in expanding space-based life sciences research. Through partnerships with government agencies and private enterprises, the ISS has served as a biomanufacturing lab bench, allowing scientists to investigate how microgravity influences disease modeling, tissue engineering, and pharmaceutical production. The transition from government-led space exploration to commercial initiatives has further accelerated progress in this field. Companies, such as Space Tango and LambdaVision, are leveraging microgravity for drug development and biomaterial production, while pharmaceutical firms like Bristol-Myers Squibb are exploring space as a novel environment for bioprocess optimization.2,6
This shift aligns with a broader trend toward the commercialization of space. With decreasing launch costs and advancements in autonomous laboratory systems, space-based biomanufacturing is increasingly seen as an economically viable industry rather than a purely scientific endeavor. Government agencies continue to play a vital role in funding and facilitating research, but the entry of private entities has expanded opportunities for translating space-based discoveries into commercially viable bioproducts.
The Expanding Market and Research Landscape
As interest in space biomanufacturing grows, investment from both public and private sectors has increased significantly. The ISS National Lab has become a central hub for biopharmaceutical and biotech companies seeking to conduct microgravity research. Startups and established industry players alike are recognizing the potential of space as a platform for drug discovery, regenerative medicine, and advanced biomaterials. NASA continues to support biomanufacturing initiatives through its Space Synthetic Biology Program, aiming to integrate synthetic biology solutions into space missions for in situ resource utilization and sustainable bioproduction.4,7
Among the key players in this evolving landscape, Axiom Space is leading efforts to develop commercial space stations that could serve as dedicated biomanufacturing hubs. Space Tango, a biotechnology company specializing in microgravity research, has pioneered automated systems for conducting cell culture and biomaterial synthesis aboard the ISS. Blue Origin and Sierra Space are also investing in commercial space habitats that could support large-scale biomanufacturing. Meanwhile, pharmaceutical companies like Bristol-Myers Squibb are leveraging microgravity to enhance bioprocessing techniques, demonstrating that space-based research has direct applications for improving therapies on Earth.6,8
The expanding market for space-based biomanufacturing is also driven by the increasing demand for biologics, gene therapies, and precision medicine. Advances in bioprinting and tissue engineering are creating opportunities for developing transplantable tissues and organoids with enhanced physiological properties. The potential for on-demand drug synthesis in space could further transform pharmaceutical supply chains, enabling the production of critical medications for astronauts on long-duration missions and providing a new paradigm for personalized medicine.1,9
As commercial investment continues to grow, biomanufacturing in space is transitioning from an experimental endeavor to a promising industry with tangible economic and scientific benefits. The next decade is expected to see the emergence of dedicated space-based production facilities, greater automation of biomanufacturing processes, and the integration of artificial intelligence and machine learning to optimize bioprocessing in microgravity. With government agencies, private companies, and academic institutions collaborating on innovative research, space biomanufacturing is poised to play a transformative role in both space exploration and global healthcare.
The Unique Advantages of Space-Based Biomanufacturing
Biomanufacturing in space offers distinct advantages that cannot be replicated on Earth. The microgravity environment of low Earth orbit fundamentally alters biological and chemical interactions, creating opportunities for enhanced protein crystallization, tissue engineering, and bioprocess optimization. Space radiation and extreme conditions present additional variables that can drive novel discoveries, while the ability to simulate aging and disease progression in microgravity provides a unique platform for drug development and biomedical research. These factors collectively position space as an unparalleled environment for advancing biotechnology, with implications for both terrestrial applications and future space exploration.1,3
Microgravity as a Differentiator
Sustained microgravity has profound effects on cellular behavior, molecular interactions, and fluid dynamics, all of which influence biomanufacturing processes. One of the most well-documented advantages of microgravity is its impact on protein crystallization, a critical step in drug development. On Earth, gravity-driven convection and sedimentation often result in imperfectly formed protein crystals. In microgravity, however, proteins crystallize with greater uniformity and fewer defects, leading to higher-resolution structures that can enhance drug design. This phenomenon has been leveraged for decades in space-based pharmaceutical research, enabling the development of improved drug formulations with enhanced stability and efficacy.1,3
Microgravity also plays a crucial role in 3D tissue culture and biofabrication, where it allows cells to grow and interact in ways that are not possible under terrestrial conditions. On Earth, gravity limits the structural integrity of engineered tissues, often requiring scaffolding materials to maintain their shape. In space, cells can assemble into more physiologically relevant three-dimensional (3D) structures without external support. This has significant implications for regenerative medicine and tissue engineering, as it facilitates the development of organoids and functional tissues for transplantation and disease modeling.1,8
Biofabrication technologies, such as 3D bioprinting, further benefit from microgravity by enabling the controlled deposition of cells and biomaterials without the interference of gravitational forces. This capability is particularly promising for producing vascularized tissues, a major challenge in regenerative medicine. Research aboard the ISS has demonstrated that space-based bioprinting can create tissue constructs with improved cell viability and organization, paving the way for future advancements in bioengineered tissues.9,10
Radiation and Extreme Conditions
In addition to microgravity, space biomanufacturing is exposed to higher levels of ionizing radiation than those found on Earth. Space radiation presents both challenges and opportunities for biotechnology. At the cellular level, radiation can induce DNA damage, accelerate mutations, and alter gene expression patterns. While these effects pose risks to biological systems, they also provide a unique opportunity to study radiation-induced genetic adaptations, which could inform cancer research, gene therapy, and synthetic biology applications.5
Radiation exposure in space can also influence microbial evolution, potentially leading to the development of more resilient microbial strains for biomanufacturing. By studying how microorganisms respond to prolonged radiation exposure, researchers can identify genetic modifications that enhance the stability and efficiency of engineered microbes used in pharmaceutical and biomaterial production. This knowledge could be applied to improve microbial fermentation processes on Earth or to develop robust microbial systems for future space missions.4,7
Space as a Model for Accelerated Aging and Disease Research
Microgravity has been shown to accelerate certain physiological changes that resemble aging and disease progression on Earth. Astronauts experience rapid bone density loss, muscle atrophy, immune system suppression, and cardiovascular changes during extended spaceflight. These effects make space a valuable model for studying aging-related diseases, such as osteoporosis, neurodegenerative disorders, and cardiovascular conditions.2,11
One of the most promising applications of space-based biomanufacturing is the use of organoids and microphysiological systems for disease modeling. Organoids are miniature, self-organizing three-dimensional tissue structures derived from stem cells, and they have emerged as powerful tools for studying human diseases. In microgravity, organoids exhibit enhanced growth and organization, making them more physiologically relevant than their Earth-grown counterparts. This has significant implications for drug testing, allowing researchers to evaluate the effects of potential therapeutics under conditions that closely mimic human physiology.7,12
Microgravity also provides a platform for studying the effects of reduced mechanical stress on tissues, which is particularly relevant for understanding degenerative diseases. For example, space-based research has revealed insights into how mechanical unloading affects musculoskeletal tissues, leading to a better understanding of osteoporosis and muscle-wasting disorders. By leveraging space-based models, researchers can develop targeted therapies for these conditions and accelerate the translation of experimental treatments to clinical applications.2,11
Key Applications of Biomanufacturing in Space
The practical applications of biomanufacturing in space span multiple disciplines, from regenerative medicine and pharmaceutical production to sustainable bioprocessing. Advances in tissue engineering, synthetic biology, and biofabrication are enabling new possibilities for medical research, drug development, and in-space resource utilization. By leveraging the advantages of microgravity, space-based biomanufacturing can enhance stem cell therapies, improve protein crystallization for drug formulation, and support sustainable industrial processes that could benefit both terrestrial industries and long-duration space missions.
Tissue Engineering and Regenerative Medicine
One of the most promising areas of space biomanufacturing is regenerative medicine, where microgravity provides a unique environment for improving stem cell therapies, growing complex tissues, and advancing biofabrication techniques. These innovations have the potential to accelerate the development of transplantable tissues, improve disease modeling, and facilitate breakthroughs in personalized medicine.
Stem Cell Proliferation and Differentiation. Microgravity has been shown to influence the behavior of stem cells, particularly their ability to proliferate and differentiate into specialized cell types. Studies have demonstrated that stem cells cultured in space exhibit increased regenerative potential, enhanced self-renewal, and improved differentiation capabilities compared to those grown under normal gravitational conditions. These findings suggest that space-based biomanufacturing could be instrumental in developing new therapies for conditions such as spinal cord injuries, neurodegenerative diseases, and organ failure.1,8
Beyond basic research, stem cell-based therapies developed in space could be translated into clinical applications on Earth, offering improved treatments for degenerative diseases and tissue damage. Additionally, the ability to mass-produce high-quality stem cells in microgravity could address challenges in cell therapy manufacturing, reducing costs and improving accessibility to regenerative treatments.
Organoids and Tissue Chips. Organoids — three-dimensional, self-organizing cellular structures that mimic the functions of human organs — have emerged as powerful tools for disease modeling and drug testing. In microgravity, organoids can grow in a more physiologically relevant manner, forming structures that better replicate their in vivo counterparts. This has significant implications for studying neurodegenerative diseases, cardiovascular disorders, and cancer progression.4,7,13
Similarly, tissue chips — microfluidic devices that simulate organ function — are being deployed in space to study human physiology and disease mechanisms under unique environmental conditions. By using these systems to test drug responses and disease progression in microgravity, researchers can gain insights that are difficult to achieve through traditional lab-based models. Space-based disease modeling has already provided valuable data on muscle atrophy, immune system function, and osteoporosis, with potential applications for aging research and precision medicine.
3D Bioprinting in Space. One of the most cutting-edge applications of space biomanufacturing is 3D bioprinting, a technology that enables the creation of complex tissue structures using living cells. On Earth, 3D bioprinting is limited by gravitational forces that cause printed tissues to collapse under their own weight. In space, however, microgravity allows for scaffold-free bioprinting, enabling the assembly of more intricate and functional tissues.1,10
Several bioprinting facilities have been deployed on the ISS to explore the potential of microgravity-enhanced tissue engineering. Techshot’s BioFabrication Facility (BFF) has successfully printed human-like tissue structures, demonstrating the feasibility of bioprinting functional tissues in space. Another initiative, 3D Bioprinting Solutions’ Organaut, aims to create vascularized tissues that could one day lead to the production of whole organs for transplantation. These advancements highlight the potential for space-based biomanufacturing to address the global shortage of donor organs while advancing the field of regenerative medicine.
Pharmaceutical Manufacturing and Drug Discovery
The pharmaceutical industry is increasingly exploring space-based biomanufacturing to optimize drug formulations, develop new therapeutics, and produce biologics with improved stability and efficacy. Microgravity conditions can enhance molecular interactions, improve drug bioavailability, and accelerate drug discovery in ways that traditional Earth-based methods cannot replicate.
Protein Crystallization and Stability. One of the most well-established benefits of space-based biomanufacturing is its ability to improve protein crystallization, a critical process in drug development. In microgravity, protein crystals form with fewer defects and greater uniformity, leading to higher-resolution structures that enhance drug design. This is particularly valuable for developing protein-based therapeutics, such as monoclonal antibodies and enzyme therapies, where precise molecular structures are essential for efficacy.2,14
Pharmaceutical companies have already leveraged space-based protein crystallization to optimize drug formulations. Research conducted aboard the ISS has led to the development of improved treatments for diseases such as cancer, Parkinson’s disease, and osteoporosis. As commercial space stations become more accessible, protein crystallization is expected to play an even larger role in drug discovery and formulation refinement.
Personalized Medicine and Targeted Drug Production. Another emerging application of space biomanufacturing is on-demand drug synthesis, where pharmaceuticals are manufactured in microgravity for immediate use. This capability is particularly relevant for long-duration space missions, where resupplying medications from Earth is impractical. By developing compact, automated bioreactors that can produce personalized medications in space, astronauts could have access to tailored treatments based on their individual health needs.9,15
On-demand drug manufacturing could also have profound implications for remote or underserved populations on Earth. If space-based production systems prove to be efficient and scalable, they could be adapted for use in areas where access to high-quality pharmaceuticals is limited. This shift toward decentralized drug production could revolutionize healthcare by making personalized medicine more accessible worldwide.
Synthetic Biology and Bioreactors. Synthetic biology is playing a growing role in space biomanufacturing, particularly in the engineering of microbial systems for drug production. By genetically modifying bacteria and yeast to synthesize valuable biomolecules, scientists can create bioreactors capable of producing pharmaceuticals, nutrients, and other essential compounds in space. NASA’s Space Synthetic Biology Program is exploring ways to use engineered microbes to manufacture medicines, vitamins, and biofuels, reducing reliance on Earth-based supply chains.3,4
Synthetic biology-driven biomanufacturing could also support planetary colonization efforts by enabling in situ resource utilization (ISRU). For example, engineered microbes could be used to convert Martian resources into oxygen, food, or pharmaceuticals, making long-term settlement on other planets more feasible. These advancements position space biomanufacturing as a key enabler of future human exploration beyond low Earth orbit.
Industrial and Sustainable Biomanufacturing
Space-based biomanufacturing is not limited to medical applications; it also holds promise for industrial biotechnology and sustainable resource utilization. By leveraging microgravity and engineered biological systems, researchers are developing innovative methods for recycling waste, producing biomaterials, and creating sustainable supply chains for space missions.
Carbon Dioxide and Waste Utilization. One of the most compelling applications of space biomanufacturing is the conversion of astronaut waste into valuable biomaterials. NASA and private companies are investigating how to use engineered microbes to break down carbon dioxide and organic waste into essential compounds, such as proteins, lipids, and bioplastics. This approach could provide astronauts with a self-sustaining source of food, medicine, and materials while reducing reliance on Earth-based resupply missions.7,15
By integrating biomanufacturing with life-support systems, space missions could achieve greater levels of sustainability, paving the way for closed-loop biological ecosystems that support long-duration exploration. Similar technologies could also be applied on Earth to improve waste recycling and carbon sequestration efforts, addressing global environmental challenges.
Biopolymers and Advanced Materials. Beyond pharmaceuticals and food production, space-based biomanufacturing is being used to create advanced biomaterials with superior properties. Researchers are developing biopolymers, nanomaterials, and composite structures in microgravity, where the absence of sedimentation and convection allows for more uniform material synthesis. These materials could be used for medical implants, flexible electronics, and lightweight aerospace components.6,16
As space biomanufacturing continues to evolve, its applications will extend beyond scientific research, driving innovation in industries ranging from healthcare to sustainable manufacturing. By harnessing the unique advantages of microgravity, biomanufacturing in space is poised to redefine how biological products are developed, produced, and applied in both extraterrestrial and terrestrial settings.
Challenges and Barriers to Scaling Space Biomanufacturing
While space biomanufacturing presents unprecedented opportunities for scientific advancement and commercial innovation, several challenges must be addressed before it can become a scalable and economically viable industry. These barriers range from logistical and technical constraints to regulatory hurdles and economic limitations. Overcoming these challenges will require coordinated efforts from government agencies, private sector stakeholders, and research institutions to develop cost-effective solutions, establish regulatory frameworks, and create sustainable business models for space-based bioproduction.
Logistical and Technical Hurdles
The most immediate challenges facing space biomanufacturing are the high costs and infrastructure limitations associated with conducting biological research and production in microgravity. Launching and maintaining biomanufacturing systems in space is prohibitively expensive, with payload costs reaching thousands of dollars per kilogram. Even as launch costs decrease with advancements in reusable rocket technology, the complexity of transporting and sustaining biological experiments in orbit remains a significant barrier.1,4
Beyond cost, the physical constraints of space-based laboratories pose additional technical challenges. Most biomanufacturing experiments currently take place aboard the ISS, where space and resources are limited. Future expansion into commercial space stations, such as those planned by Axiom Space and Blue Origin, may alleviate some of these constraints, but designing and deploying fully functional biomanufacturing systems that can operate autonomously in microgravity remains an ongoing challenge.4,12
Automation and artificial intelligence (AI) are essential for making space-based biomanufacturing more feasible, but current autonomous bioprocessing technologies remain limited. Advanced AI-driven systems capable of monitoring and optimizing bioproduction in real time are still in development, and their integration into space-based platforms will require further testing and refinement. In particular, automated cell culture, tissue engineering, and microbial bioprocessing systems need to be optimized for remote operation, reducing the need for direct astronaut intervention.9,12
Additionally, maintaining the stability and reproducibility of biological processes in space presents unique technical difficulties. Space radiation, fluctuating temperature conditions, and microgravity-induced physiological changes can all impact biomanufacturing outcomes, necessitating the development of specialized protocols and hardware to ensure consistency in production. Until these technical and logistical barriers are addressed, large-scale space-based biomanufacturing will remain largely experimental rather than commercially scalable.
Regulatory and Ethical Considerations
As space biomanufacturing evolves from an experimental endeavor into a potential industry, regulatory frameworks will need to be adapted to govern the safety, quality, and oversight of biologics produced in space. Current pharmaceutical and biomanufacturing regulations, such as those enforced by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulatory bodies, are designed for terrestrial production environments. These regulations do not yet account for the unique conditions of space-based bioprocessing, raising questions about how to ensure product quality, consistency, and compliance with existing safety standards.11
A key regulatory challenge involves the validation and standardization of biomanufacturing processes in microgravity. How should regulators evaluate biologics, bioengineered tissues, and synthetic biology products produced in space? Can space-grown therapeutics be considered fundamentally equivalent to their Earth-grown counterparts, or will they require separate approval pathways? These questions remain unresolved and will need to be addressed before space-based biomanufacturing can move beyond research and into commercial production.11
Beyond regulation, ethical concerns surrounding genetic engineering, biohazards, and long-term human exposure to space-based biological systems must also be considered. The use of synthetic biology in space raises concerns about biosecurity, particularly regarding the accidental release or uncontrolled mutation of genetically modified organisms. While containment protocols are in place for current space-based biological research, future large-scale biomanufacturing operations will require more stringent biohazard management strategies to mitigate potential risks.7,12
Additionally, as space biomanufacturing advances, ethical considerations regarding human enhancement and biomedical experimentation in space may come to the forefront. For example, could gene-editing technologies, such as CRISPR, be used in space to engineer astronauts with enhanced resistance to radiation or other environmental stresses, or even to aging? If so, what ethical implications would this have for human spaceflight and long-term space colonization? These discussions are still in their early stages but will become increasingly relevant as biomanufacturing in space progresses.
Economic Viability and Market Development
While the scientific and technological potential of space biomanufacturing is clear, its economic sustainability remains uncertain. The current funding landscape for space-based biomanufacturing is heavily reliant on government support, with agencies such as NASA, ESA, and the ISS National Lab providing much of the funding for research initiatives. Private sector investment has increased in recent years, but commercialization remains in its infancy, and the long-term business model for space-based biomanufacturing has not been established.1,5
One of the biggest economic hurdles is proving that space-based biomanufacturing can generate products that justify the costs of production. While microgravity offers unique advantages for drug discovery, protein crystallization, and regenerative medicine, terrestrial biomanufacturing is already highly optimized and cost-efficient. Unless space-grown biologics offer clear and substantial benefits over Earth-based alternatives, it may be difficult to attract sustained private investment in this field.5
To address this challenge, public–private partnerships (PPPs) will be critical in sustaining investment and accelerating commercialization. Collaborative models that involve government agencies, biotech startups, and established pharmaceutical companies could help distribute the financial risks associated with space biomanufacturing while leveraging private-sector innovation to drive progress. Initiatives such as the ISS National Lab’s research partnerships with Bristol-Myers Squibb and Space Tango demonstrate how strategic alliances can facilitate the transition from experimental research to commercial production.7,12
Beyond traditional biotech applications, developing new markets for space-derived biomaterials could enhance economic viability. If space-based biomanufacturing proves valuable for producing specialized materials, such as biopolymers, advanced nanomaterials, or bioengineered tissues for transplantation, these products could create new revenue streams that support the industry’s long-term growth.6,16
Ultimately, the economic future of space biomanufacturing will depend on continued innovation, cost reductions, and the ability to demonstrate real-world value. As space-based research expands and commercial platforms become more accessible, the industry will need to balance scientific ambition with financial feasibility to establish a sustainable path forward.
The Future of Biomanufacturing in Space
As space biomanufacturing evolves from experimental research into a viable industry, the next decade will be defined by increasing commercialization, enhanced automation, and integration with deep-space exploration efforts. The transition from ISS-based studies to private space stations will open new opportunities for pharmaceutical production, regenerative medicine, and synthetic biology applications in microgravity. Furthermore, biomanufacturing will play a critical role in supporting long-term human habitation beyond Earth, particularly on the Moon and Mars. By leveraging automation, AI, and sustainable bioproduction strategies, future space missions will be able to manufacture essential biomaterials, medicines, and even food on-site, reducing dependency on Earth-based supply chains.
The Next Decade: From ISS to Commercial Platforms
For more than two decades, the ISS has served as the primary research platform for space-based biomanufacturing. However, with the planned retirement of the ISS in the 2030s, the industry must transition to new commercial space stations to continue advancing research and scale up production. Several private companies are already working to develop these platforms, positioning themselves as the next-generation hubs for microgravity-based bioprocessing.1,6
Axiom Space is leading efforts to construct the first privately funded space station, which will initially be attached to the ISS before operating independently. Axiom’s station is expected to host pharmaceutical and biotech companies seeking to leverage microgravity for research and production. Similarly, Blue Origin and Sierra Space are developing the Orbital Reef space station, a commercial platform designed to support scientific research, manufacturing, and tourism. These emerging facilities will provide dedicated infrastructure for biomanufacturing, potentially reducing costs and increasing accessibility for private sector investment.
As space-based research expands, commercial stations could serve as biopharma production hubs that supply Earth with advanced therapeutics, protein-based drugs, and engineered tissues. If scalable and economically viable, these stations may establish new supply chains for high-value biologics that benefit from microgravity-enhanced processing.
Integration with Planetary Exploration and Lunar/Martian Missions
While space biomanufacturing holds promise for commercial applications in low Earth orbit, its greatest long-term potential lies in its ability to support human exploration beyond Earth. Establishing sustainable settlements on the Moon and Mars will require the ability to produce medicines, food, and essential biomaterials in situ, reducing reliance on costly and logistically complex resupply missions from Earth. Biomanufacturing will be a cornerstone of this effort, enabling astronauts to produce what they need on demand using engineered microbes, plant-based systems, and biofabrication techniques.4,8
NASA’s Artemis program aims to establish a sustained human presence on the Moon by the end of the decade, serving as a proving ground for technologies that will be used in future Mars missions. Biomanufacturing will play a key role in this effort, with potential applications including:
Microbial bioreactors to produce pharmaceuticals and nutrients.
On-site tissue engineering and wound healing solutions for astronaut health.
Bio-based construction materials for building habitats using lunar or Martian resources.
On Mars, where resupply missions could take years, self-sufficient biomanufacturing systems will likely be critical for survival. Engineered microbes could be used to generate oxygen, fuel, and essential biomolecules from Martian resources, while space-adapted crops and algae-based systems could support long-term food production. These efforts will not only enable deep-space exploration but also contribute to the development of sustainable closed-loop biomanufacturing systems that could benefit Earth-based industries as well.
The Role of AI, Automation, and Robotics
Scaling biomanufacturing in space will require significant advancements in automation, AI-driven optimization, and robotic-assisted bioprocessing. Given the high costs and logistical constraints of human-operated space laboratories, future biomanufacturing platforms will need to function with minimal human intervention.
AI-powered systems can enhance space-based biomanufacturing by:
Monitoring and adjusting bioprocess parameters in real time to optimize yields.
Predicting and preventing biocontamination or equipment failures using machine learning algorithms.
Enabling remote operation of bioreactors and tissue engineering systems, reducing the need for astronaut oversight.
Robotic systems will also be crucial for handling delicate biological materials in microgravity. Automated pipetting systems, biofabrication robots, and AI-driven cell culture platforms are already being tested in space, laying the foundation for fully autonomous biomanufacturing facilities in the future.10
The combination of AI, robotics, and microgravity-optimized bioprocesses will not only improve the efficiency of space-based manufacturing but could also lead to advancements in terrestrial biotech industries, where automation is increasingly used to enhance drug discovery, personalized medicine, and industrial bioprocessing.
Closing the Loop: Sustainable and Circular Biomanufacturing Systems
For space biomanufacturing to be viable over the long term, it must evolve into a self-sustaining, closed-loop system that efficiently recycles resources and minimizes waste. Current research is exploring ways to integrate biomanufacturing with life-support systems to create a circular ecosystem in which biological waste, carbon dioxide, and other by-products are repurposed for useful applications.3,15
Potential circular biomanufacturing strategies include:
Microbial systems that convert astronaut waste into biofuels, nutrients, and pharmaceuticals.
Algae-based oxygen generation and food production systems that integrate with closed-loop life support.
Biodegradable materials that can be repurposed into new bioproducts instead of generating space debris.
These technologies could reduce the mass and cost of space missions by enabling astronauts to produce essential resources on-site rather than relying on shipments from Earth. On a larger scale, sustainable space biomanufacturing could inform new approaches to addressing environmental challenges on Earth, such as waste management, carbon sequestration, and circular bioeconomies.
As space agencies and private companies continue to develop these capabilities, the vision of a fully autonomous biomanufacturing ecosystem — capable of sustaining human life beyond Earth — moves closer to reality. The next decade will be a crucial period for advancing these technologies and demonstrating their feasibility in operational space environments.
A Future in the Stars
Biomanufacturing in space is emerging as a transformative field with far-reaching implications for medicine, industry, and space exploration. By leveraging the unique conditions of microgravity, scientists and engineers are unlocking new possibilities for drug development, regenerative medicine, and industrial biotechnology. Advances in protein crystallization, tissue engineering, and synthetic biology are demonstrating that space-based biomanufacturing can enhance biomedical research and accelerate the development of next-generation therapeutics. At the same time, innovations in sustainable bioprocessing and circular bioeconomies are laying the groundwork for self-sufficient life-support systems that will be critical for deep-space exploration.
As commercial space stations replace the International Space Station, private sector biomanufacturing will have new opportunities to expand. Companies such as Axiom Space and Blue Origin are already developing infrastructure that could support large-scale bioproduction in microgravity, while pharmaceutical and biotech firms are exploring ways to integrate space-based research into their product development pipelines. Beyond low Earth orbit, biomanufacturing will play a key role in enabling long-duration missions to the Moon and Mars by providing astronauts with the capability to produce medicines, biomaterials, and essential life-support resources on demand.
To fully realize the potential of space biomanufacturing, sustained investment and interdisciplinary collaboration will be essential. Governments, private companies, and academic institutions must work together to overcome technical and regulatory challenges, establish viable economic models, and accelerate the transition from experimental research to commercial-scale production. PPPs will be particularly important in bridging the gap between space-based discoveries and real-world applications, ensuring that the benefits of space biomanufacturing extend beyond space exploration and into global healthcare, industrial sustainability, and biopharmaceutical innovation.
Looking ahead, the convergence of artificial intelligence, automation, and synthetic biology will further accelerate progress, allowing biomanufacturing systems to function with minimal human intervention. If successful, space-based biomanufacturing could revolutionize not only space exploration but also terrestrial industries, unlocking new possibilities for regenerative medicine, personalized drug production, and sustainable biotechnology.
With continued investment and interdisciplinary collaboration, biomanufacturing in space is poised to become one of the most transformative frontiers in modern biotechnology, reshaping how biological products are developed, manufactured, and applied both on Earth and beyond. As we enter this new era of space-based innovation, the prospect of harnessing the full potential of microgravity for biomanufacturing is no longer a distant vision—it is an unfolding reality that will redefine the future of science, industry, and human exploration.
Our parent company, That’s Nice, is committed to supporting the companies and innovators driving the next wave of pharma and biotech innovation. To celebrate That’s Nice’s 30th anniversary, Pharma’s Almanac is diving into 30 groundbreaking advancements, trends, and breakthroughs that have shaped the life sciences, highlighting the industry-defining milestones our agency has had the pleasure of growing alongside. Here’s to 30 years of innovation and the future ahead!
References
1. Giulianotti, Marc, et al. “Opportunities for Biomanufacturing in Low Earth Orbit: Current Status and Future Directions.” Preprints.org. 2 Aug. 2021.
2. Smith, Amelia Williamson. “The Future of Biomanufacturing in Space: A Unique Opportunity.” ISS National Laboratory. 2 Aug. 2021.
3. Averesch, Nils JH, et al. “Microbial biomanufacturing for space-exploration—what to take and when to make.” Nature Communications. 14:2311 (2023).
4. “Space Synthetic Biology.” NASA. Accessed 13 Mar. 2025.
5. Berliner, Aaron J. “Towards a Biomanufactory on Mars.” Front. Astron. Space Sci. 18 Jul. 2021.
6. Ruggles, Megan. “Bristol Myers Squibb takes biomanufacturing to space.” Manufacturing Dive. 24 Mar. 2023. https://www.manufacturingdive.com/news/bristol-myers-squibb-takes-biomanufacturing-to-space/645864/
7. “In-Space Biomanufacturing for Human Health Innovation Hub.” University of Florida, Department of Pharmacodynamics. Accessed 13 Mar. 2024.
8. “Opportunities for Spaceflight to Advance Stem Cell Science, Biomanufacturing, and Disease Modeling.” Genetic Engineering & Biotechnology News. 3 Jan. 2022.
9. Loeza, Brenda Cansino, et al. “Biomanufacturing in Space: New Concepts and Paradigms for Process Design.” AIChE Annual Meeting, San Diego, CA. 27–31 Oct. 2024.
10. Cansino-Loezaa, Brenda, et al. “Biomanufacturing in Space: New Concepts and Paradigms for Process Design.” Systems & Control Transactions. 3: 674–680 (2024).
11. Sharma, Arun, et al. “Biomanufacturing in low Earth orbit for regenerative medicine.” Stem Cell Reports. 17:1–13 2022.
12. “Unlocking the Potential of Space Biotechnology with CUBES.” UC Berkeley Space Center. Accessed 13 Mar. 2025.
13. Moroni, Lorenzo et al. “What can biofabrication do for space and what can space do for biofabrication?” Trends in Biotechnology. 40:P398–411 (2022).
14. Ballard, Shawn. “WashU students contribute to biomanufacturing in space." WashU The Source. 3 Oct. 2023.
15. Miller , Beth. “Researchers aim to develop space biomanufacturing from carbon dioxide, astronaut wastes.” WashU McKelvey School of Engineering. 25 Nov. 2024. l
16. Lee, Hakyung, et al. “Developing an alternative medium for in-space biomanufacturing.” Nature Communications. 16: 728 (2025).